Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
Prognostic impact of extranodal extension in stage 1B gastric carcinomas
Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors.
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.
A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer.
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.
Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients.
The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis.
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas.
Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients.
Clinical and histopathological analysis of 46 cases of cutaneous adverse reactions to imatinib
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer.
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1.
Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib.
Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis
Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).
Current Status and Challenges of Cancer Clinical Trials in Korea.
Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
Intraoperatively Assessed Macroscopic Serosal Changes in Patients with Curatively Resected Advanced Gastric Cancer: Clinical Implications for Prognosis and Peritoneal Recurrence
Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer.
Predicting the efficacy of an oral paclitaxel formulation (DHP107) through modeling and simulation.
Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib.
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications.
Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.
A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA).
A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group.
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors
Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Heterotopic pancreas of the jejunum: associations between CT and pathology features.
Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Prognostic significance of neuroendocrine components in gastric carcinomas.
Quality of life in the trastuzumab for gastric cancer trial.
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Significant symptom relief with hepatic artery embolization in a VIPoma with liver metastases : A case report
The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.
A UGT1A1 *28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S?1 (DOS) chemotherapy followed by surgery and adjuvant S?1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201).
Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study.
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Diagnosis and Treatment of Gastrointestinal Stromal Tumor.
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101)
Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.
Imatinib plasma monitoring?guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor (GIST) patients.
Management of colon cancer: resource-stratifi ed guidelines from the Asian Oncology Summit 2012
Management of gastric cancer in Asia: resource-stratified guidelines.
Phase I Study Investigating Everolimus Combined With Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.
Phase II study of Dovitinib in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors after Failure of Imatinib and Sunitinib.
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
Postoperative Nodal Status and Diffuse- Type Histology are Independent Prognostic Factors in Resectable Advanced Gastric Carcinomas after Preoperative Chemotherapy.
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
Serum CA 19-9 as a prognostic factor in patients with metastatic gastric cancer.
Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses.
unitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial.
The Effects of Surgical Cytoreduction Prior to Imatinib Therapy on the Prognosis of Patients with Advanced GIST.
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer: A Prospective, Multicenter Trial of the Korean Cancer Study Group.
A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity.
Adjuvant Treatments for Localized Advanced Gastric Cancer: Differences among Geographic Regions.
Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases:analysis of prognosis and patterns of recurrence
An update of adjuvant treatments for localized advanced gastric cancer
Bevacizumab in Combination With Chemotherapy as First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial.
Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure.
Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea.
Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma According to Baseline Status: Subset Analyses of the Phase III Sorafenib Asia-Pacific Trial
Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma According to Baseline Status: Subset Analyses of the Phase III Sorafenib Asia-Pacific Trial.
Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.
Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
Management of advanced gastric cancer
Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012.
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
Phase II and UGT1A1 genotype study of 3-weekly irinotecan with individualized patient dose escalation as salvage chemotherapy for advanced gastric cancer.
Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
Phase II, Open-label Study of Brivanib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Predictors of Recurrence After Resection of Small Gastric Gastrointestinal Stromal Tumors of 5 cm or Less.
Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients.
Venous thromboembolism (VTE) in patients with advanced gastric cancer: An Asian experience.
A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction.
A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models.
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
Adjuvant Chemotherapy for Small Bowel Adenocarcinoma after Curative Surgery.
Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A ranmomized, double-blind, placebo-controlled phase III study.
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Clinical impact of EUS-guided Trucut biopsy results on decision making for patients with gastric subepithelial tumors ≥2 cm in diameter.
Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
Phase I/II study of a combination of docetaxel, capecitabine and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Defi ne the Optimal Sequence of Chemotherapy and Radiotherapy: 10-Year Follow-Up.
Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow up.
Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report.
Results and implications of the ToGA (Trastuzumab for GAstric Cancer) trial.
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.
Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study.
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.
The diagnosis and management of gastric cancer:expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
한국인 비호지킨림프종의 백혈병성 골수침습에 대한 임상혈액학적 소견
Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea.
Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib
Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines.
Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer.
Palliative Treatment of Malignant Gastric Outlet Obstructions with a Large-diameter Metallic Stent: Prospective Preliminary Study.
Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin (DXO) combination chemotherapy in patients with previously untreated advanced gastric cancer.
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer
Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
Recent advances in chemotherapy for advanced gastric cancer.
Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Gemcitabine으로 치료된 홍피증성 균상식육종 1예
A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Capecitabine/Cisplatin Versus 5-Fluorouracil/Cisplatin as First-Line Therapy in Patients with Advanced Gastric Cancer: a Randomized Phase III Trial.
Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific region with Advanced Hepatocellular Carcinoma: Results of a Phase III Randomised, Double-Blind, Placebo-Controlled Trial Conducted in the Asia-Pacific Region.
Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors Is Independent of KIT Mutational Status.
Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors.
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.
Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with nresectable Locally Advanced or Metastatic Gastric Cancer.
Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Phase II study of irinotecan in combination with capecitabine as a first-line chemotherapy in Asian patients with inoperable hepatocellular carcinoma.
Reply to 'Are we representing the true population in oncology trials?'
The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer
A case of primary effusion lymphoma in a patient with alcoholic liver cinhosis.
A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.
A phase II study of paclitaxel and capecitabine combination chemotherapy as a first-line therapy for advanced gastric cancer.
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
A randomized multi-center phase II trial of capecitabine versus S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis
Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer (AGC).
Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group.
Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis
Infarction and Perforation of the Small Intestine due to Tumor Emboli from Disseminated Rectal Cancer.
PDGFR(α) Gene Mutation and Protein Expression in Gastrointestinal Stromal Tumors
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Primary central nervous system marginal zone B-cell lymphoma of the Basal Ganglia mimicking low-grade glioma: a case report and review of the literature.
Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck
Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.
capecitabine in the treatment of advanced gastric cancer.
A Phase II Study of Cetuximab (Erbitux(R)) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
A phase I and pharmacologic study of belotecan in combination with Cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Both-sided Intra-atrial Intracardiac metastases as the Initial Presentation of Testicular Seminoma.
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Yoon-Koo Kang
Cetuximab plus FOLFIRI for irinotecan-refractory metastatic colorectal cancer: A retrospective analysis
Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea
Combination chemotherapy with capecitabine (x) and Cisplatin (p) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Cutaneous Metastasis Resembling Acute Dermatitis in Patient with Advanced Gastric Cancer.
Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Extrapulmonary Small Cell Carcinoma: Single Center Experience with 61 Patients.
Metallic stent placement in the palliative treatment of malignant gastroduodenal obstructions: prospecitve evaluation of results and factors influencing outcome in 213 patietns.
Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.
Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours
Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia.
원발 위장관 미만 대 B세포 림프종의 임상상과 International Prognostic Index의 적용.
A case of intrahepatic cholangiocarcinoma with orbital metastasis
A case of leukemic pleural infiltration in atypical chronic myeloid leukemia.
Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
Gemcitabine Single or Combination Chemotherapy in Post Anthracycline and Taxane Salvage Treatment of Metastatic Breast Cancer: Retrospecive Analysis of 124 Patients.
Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients
Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases
Patterns of Progression in Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate
Response to Imatinib in KIT- and PDGFRA-Wild Type Gastrointestinal Stromal Associated with Neurofibromatosis Type 1
호지킨 림프종 완치 후 발생한 비호지킨 림프종 1예
A Randomised Crossover Study Comparing Ramosetron plus Dexamethasone with Ramosetron Alone in the Prevention of Cisplatin-Induced Emesis
Concurrent Male Gynecomastia and Testicular hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
Concurrent Male Gynecomastia and Testicular hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor.
Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines
ESHAP plus G-CSF as an effective peripheral blood prgenitor cell mobilizartion regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF
Efficacy and Safety Study of Docetaxel as Salvage Chemotherapy in Metastatic Gastric Cancer Failing Fluoropyrimidine and Platinum Combination Chemotherapy.
Fine Needle Aspiration Cytology of the Plasmablastic Lymphoma in Human Immunodeficiency Virus(HIV) Negative Patient - A Case Report-
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: A Korean Cancer Study Group Trial
Phase II Study of Paclitaxel and Carboplatin in Advanced Gastric Cancer Previously Treated with 5-Fluorouracil and Platinum
Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
The GIST of a stromal tumor.
폐에 생긴 원발성 NK 세포 림프종 1예
재발성 원발성 중추신경계 림프종 환자에서 고용량 Cytarabine과 Etoposide 항암화학요법 후 자가 조혈모 세포 이식 3예
고형암 환자에서 항암화학요법 후 호중구감소증에 대한 류코업?(Filgrastim, rhG-CSF)의 안전성 및 유효성: 그라신?과의 다기관 비교 임상시험
Alternative therapy and abnormal liver function during adjuvant chemotherapy in breast cancer patients
Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane
Clinical value of cyclooxygenase-2 expression in human breast carcinoma
Clinicopathological features of eight Korean cases of primary hepatic lymphoma
Complete remission of high gastric MALT lymphoma after Helicobacter pylori eradication: a case report
Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy.
Leptomeningeal carcinomatosis in gastric cancer
Primary Malignant Lymphoma of the Breast: Clinicopathological Study of Nine Cases
Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors.
Prospective Phase II Study of Preoperative Chemoradiation with Capecitabine in Locally Advanced Rectal Cancer
Prospective phase II study of Preoperative chemoradiation with capecitabine in locally advanced rectal cancer
Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer.
위장관 간질종양의 악성도의 예측
고형암 환자에서 항암화학요법후 발생한 호중구 감소증에 대한 류코그린(G-CSF)의 제3상 다기관 공동임상시험
A Multicenter, Phase III Clinical Trial of Leucogreen®(G-CSF) for Chemotherapy-Induced Neutropenia in Solid Tumors.
Clinicopathologic analysis of ocular adnexal lymphomas: Extranodal marginal zone B-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients.
High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean multicenter study.
Locally Advanced Acinar Cell Carcinoma of the Pancreas Successfully Treated by Capecitabine and Concurrent Radiotherapy: Report of Two Cases(Case Report)
Natural killer cells in human peripheral blood and primary cutaneous natural killer cell lymphomas may express cutaneous lymphocyte antigen.
Oral doxifluridine plus leucovorin in metastatic colorectal cancer. Randomized phase II trial with intravenous 5-fluorouracil plus leucovorin.
Phase II study of capecitabine plus cisplatin as first line chemotherapy in advanced biliary cancer.
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer
Primary intestinal lymphoma
Subclassification of diffuse large B-cell lymphomas according to the REAL classification: Distinction of immunoblastic and non-immunoblastic subtypes.
The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBsAg)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.
원발성 삼출액 림프종 3례
A case of chylous ascites associated with non-Hodgkin’s lymphoma and liver cirrhosis.
Chemotherapeutic agents used in elderly stomach cancer patients.
Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
Editorial. Gastrointestinal stromal tumor with a new concept and promising treatment.
Fine needle aspiration cytology of CD56-positive natural killer/T-cell lymphoma of soft tissue.
Intensified induction followed by high-dose therapy with autologous peripheral blood stem cell support in poor-prognosis aggressive non-Hodgkin’s lymphoma: results of a pilot study.
Mucosa-Associated Lymphoid Tissue Lymphoma Following Kidney Transplantation.
Nephrotoxicity of Heptaplatin : A Comparative study with Cisplatin in Advanced Gastric Cancer.
Phase II study of gemcitabine, UFT, and leucovorin in patients with advanced pancreatic cancer.
Polymerase chain reaction-based diagnosis of bone marrow involvement in 170 cases of non-Hodgkin lymphoma.
Primary Non-Hodgkin's Lymphoma of Bone : A Single Institution Experience.
Primary malignant lymphoma of the breast - clinicopathologic study of 9 cases
Ramosetron for the Prevention of Cisplatin-Induced Acute Emesis: A Prospective Randomized Comparison with Granisetron.
Randomized Trial of Postoperative Adjuvant therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: A Preliminary Report
The effect of intensified induction using Vanderbilt regimen in patients with an intermediate grade non-Hodgkin's lymphoma having 2 or 3 adverse factors on the age-adjusted international prognostic index.
A phase II trial of UFT-E and oral leucovorin in advanced colorectal cancer.
A prospective correlation of Lauren's histological classification of stomach cancer with clinicopathological findings including DNA flow cytometry.
Allogeneic non-myeloablative stem cell transplantation for the patients with heavily pre-treated refractory lymphoma.
Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study.
Retrospective analysis of treatment outcome and prognostic factors in multiple myeloma.
퇴행성 대세포성 T 세포 림프종과 형질세포백혈병 병발 1례
Acute exacerbation of hepatitis in hepatitis B virus carriers with non-Hodgkin's lymphoma after chemotherapy.
Chemotherapy with five-day continuous infusion of 5-fluorouracil(5-FU) plus cisplatin for advanced gastric cancer: Significance of 5-FU concentration monitoring.
Cisplatin-induced peripheral neuropathy in patients with advanced gastric cancer.
Drug resistance to 5-fluorouracil and overexpression of thymidylate synthase mRNA in human gastrointestinal malignancies.
Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells.
p53 gene mutation by direct DNA sequencing predicts poor survival in patients with stomach cancer.
A Phase 2 Trial of Verapamil for Reversal of Drug Resistance in Refractory Non - Hodgkin's Lymphoma.
A Phase II Trial of VAD ( Vincristine , Doxorubicin and Dexamethasone ) Chemotherapy for Previously Untreated Multiple Myeloma.
A Pilot Study of the Efficacy and Safety of rhGM-CSF Mouthwash on Oral Mucositis in Cancer Patients during/after Chemotherapy.
A phase II trial of DA-125, a novel anthracycline, in advanced non-small cell lung cancer.
Adjuvant PEF(Cisplatin, Etoposide, and 5-Fluorouracil) Chemotherapy following curative resection of gastric adenocarcinomas involving esophagogastric junction.
Clinicopathologic Charcteristics of Korean Non - Hodgkin's Lymphomas Based on REAL Classification.
Clinicopathologic Charcteristics of Korean Non-Hodgkin's Lymphomas Based on REAL Classification.
Clinicopathologic analysis of 501 non-Hodgkin's lymphomas in Korea according to the revised European-American classification of lymphoid neoplasms.
Correlation between Clinical Outcome and Proliferation Index in Diffuse Large B-Cell Lymphoma.
Retrospective Analysis of Treatment Outcome and Prognostic Factors in Hodgkin's Disease.
TGF-beta-induced cell-cycle arrest through the p21(WAF1/CIP1)-G1 cyclin/Cdks-p130 pathway in gastric-carcinoma cells.
The Effect of Combination Chemotherapy with Vinorelbine, Carboplatin, and Ifosfamide in Patients with Advanced Non-Small Cell Lung Cancer.
The Efficacy of PEFL Chemotherapy and Identification of Favorable Subgroups in Patients with Carcinomas of Unknown Primary Origin.
A Case of Malignant Lymphoma of the Thyroid Gland.
A Case of Mantle Cell Lymphoma Confirmed with bcl-l/JH Rearrangement by PCR and Cyclic D1 Overexpression by Immunohistochemistry-.
A Phase Ⅱ Trial of EPOCH (Etoposide, Vincristine, Doxorubicin, Cyclophosphamide and Prednisolone) Chemotherapy for Previously Treated Non-Hodgkin’s Lymphoma.
A Phase Ⅱ Trial of PEF(Cisplatin, Etoposide, 5-Fluorouracil) Chemotherapy for Metastatic Stomach Cancer.
C-MOPP/ABV (Cyclophosphamide, Vincristine, Procarbazine, Prednisolone/ Doxorubicin, Bleomycin, Vinblastine) Hybrid Chemotherapy for Previously Untreated, Advanced Hodgkin Disease.
Cdk4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells.
Cellular resistance to adriamycin conferred by enhanced Rb expression is associated with increased mdr1 expression.
Diagnosis and Treatment of Cancer Pain.
Efficacy of Low-Dose G-CSF for the treatment of Chemotherapy-Induced Febrile Neutropenia.
High-Dose Chemotherapy with Vanderbilt Regimen and CSF Support for High-Risk Aggressive Non-Hodgkin’s Lymphoma.
Primary CHOP Chemotherapy Followed by Involved Field Radiation Therapy in Clinical Stage I or II Aggressive Non-Hodgkin's Lymphomas.
Transarterial Chemoembolization(TACE) for Hepatocellular Carcinoma: Comparison of Adriamycin alone vs. Cisplatin alone vs. Adriamycin + Cisplatin.
A Case of Non-Hodgkin’s Lymphoma Associated with Hepatocellular Carcinoma.
A Case of Pyloric Obstruction Caused by Self-expandable Metallic Stent for Palliation of Malignant Dysphagia.
A Phase II Study of AP(Doxorubicin, Cisplatin) Chemotherapy in Patients with Advanced Hepatocellular Carcinoma.
Analysis of Prognostic Factors and Application of International Prognostic Index Model to Determine the High Risk Group for the Treatment of Aggressive Non-Hodgkin’s Lymphoma.
Effect of GM-CSF for Myelosuppression Induced by Dose-intensive Chemotherapy: Comparison of Prophylactic vs. Therapeutic Administration.
Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization.
Phase Ⅱ Study of Concurrent Chemotherapy with Etoposide and Cisplatin (EP) and Radiation Therapy for Unresectable Stage Ⅲ Non-small Cell Lung Cancer.
Prognostic Factor Analysis of Small Cell Lung Cancer: Appropriateness of Two Staging System.
The Results of Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer.
Three Cases of Interstitial Pneumonitis Developed after Anticancer Chemotherapy Containing Cyclophosphamide.
VACOP-B (Etoposide /Doxorubicin/Cyelophosphamide/Vincristine/Prednisolone/Bleomycin) Combination Chemotherapy for the Treatment of Intermediate and High Grade Non-Hodgkin’s Lymphoma
A case of Ph Chromosone-negative, bcr/abl rearrangement-positive chronic myelogenous leukemia presenting with dermopathy and lymphadenopathy.
A case of primary mediastinal germ cell tumor associated with Klinefelter’s syndrome.
A case of synchronous triple primary cancers in larynx, esophagus, and stomach.
A phase II trial of cisplatin, etoposide& 5-fluorouracil (PEF) combination chemotherapy in patients with metastatic or recurrent esophageal cancer.
Clinical Reversal of Multidrug Resistance.
Clinical effects of recombinant human erythropoietin (Eprex) in anemic patients with cancer receiving chemotherapy.
Drug resistance and its reversal.
Neoadjuvant chemotherapy with cisplatin, etoposide, and 5-fluorouracil (PEF) followed by surgery in patients with locally advanced esophageal cancer: a pilot study.
Sensitive assay for verapamil in plasma using gas-liquid chromatography with nitrogen-phosphorus detection.
A case of Cushing’s syndrome associated with ectopic corticotrophin production in patient with small cell lung cancer.
Expression of mdr-1 in refractory lymphoma: Quantitation by polymerase chain reaction and validation of the assay.
The effect of combination chemotherapy with mitomycin-C, vinblastine, and cisplatin (MVP) in patients with advanced non-small cell lung cancer.
A phase III sudy on the effect of Leukogen (Recombinant human granulocyte-macrophage colony stimulating factor) on myelosuppressioninduced by chemotherapy in patients with lung cancer and gastric cancer.
Adult T-Cell Leukemia / Lymphoma in a Korean - A case report.
Mutation of K-ras oncogene in non-small cell lung cancer.
A case of congenital hepatic fibrosis associated with nodular nontoxic goiter.
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin-C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Effects of Granulocyte-Macrophage Colony-Stimulating Factorand Granulocyte Colony-Stimulating Factor on Colony Formation of Human Cancer Cell Lines.
COP-BLAM III (Cyclophosphamide/ Vincristine/ Prednisone/ Bleomycin/ Adriamycin/ Procarbazine) combination chemotherapy for the treatment of intermediate and high grade non-Hodgkin’s lymphoma.
COP-BLAMV (cyclophosphamide/ vincristine / prednisone / bleomycin / adriamycin / procarbazine) combination chemotherapy for the treatment of intermediate and high grade non-Hodgkin’s lymphoma.
Induction of antileukemic cytotoxicity from peripheral blood lymphocytes of patients with acute myeloid leukemia.
Pathological observation in locally advanced gastric carcinomas after preoperative chemotherarpy.
5-fluorouracil, epirubicin, cisplatin (FEP) and 5-fluorouracil, cisplatin (FP) combination chemotherapy for advanced pancreatic carcinoma.
A case of adriamycin-induced cardiomyopathy confirmed by endomyocardial biopsy.
Antitumor activity of adriamycin and the analogues, THP-adriamycin and epirubicin, against human tumor cell lines
Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, prednisone (C-MOPP) in Hodgkin’s disease
Differential depression of lymphocyte subsets according to stage in stomach cancer.
Defective generation of lymphocyte-activated killer(LAK) activity in patients with advanced stomach cancer.
Depression of peripheral blood lymphocyte subsets in patients with primary hepatoma.
Diphenylhydantoin-induced pure red cell aplasia.
Microangiopathic hemolytic anemia (MAHA) associated with cancer.
Modification of Resistance to Adriamycin by Cyclosporin_A in Human Lung Cancer Cell Line (PC-14).
Phase I trial of recombinant interferon gamma (LBD-001) in cancer patients.
Remission induction with vincristine, prednisolone, daunorubicin, L-asparaginase in adult acute lymphocytic leukemia.
A case of peripheral arterial embolism by malignant tumor.
A case of radiation-induced pericarditis and myocardial fibrosis.
CHOP and CHOP/IMVP-16 combination chemotherapy for the treatment of intermediate and high grade non-Hodgkin’s lymphoma.
Combination chemotherapy with cisplatin, etoposide, and vinblastine (PEV) in the advanced non-small cell lung cancer.
Continuous infusion of 5-fluorouracil and cisplatin (FP) for metastatic or recurrent uterine cervical cancers.
Intrapleural administration of OK-432 in patients with malignant pleural effusion.
5-FU infusion and cisplatin in patients with disseminated or recurrent head and neck cancer.
Combination chemotherapy with cyclophosphamide, adriamycin, methotrexate and 5-fluorouracil (CAMF) for the metastatic breast cancer.
A case of POEMS syndrome
Continuous infusion of 5-fluorouracil and mitomycin-C (FM) for metastatic colorectal cancers.
Dimethyl Triazeno Imidazole Carboxamide(DTIC) therapy in metastatic malignant melanoma.
